NRAS and melanoma: Treatment with 6-thio-dG impaired the viability of NRAS-mutant melanoma cells (Fig. 2a, b; Supplementary Figure S8a–b), including cells driven by the secondary mutations in NRAS derived from melanoma patients with acquired resistance to BRAF and MEK inhibitors (Fig. 2b).